Other
2029
Merck & Co. 2029 increased by 57.1% to $3.30B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 57.1%, from $2.10B to $3.30B. Over 5 years (FY 2020 to FY 2025), 2029 shows an upward trend with a 18.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026
How to read this metric
Consistent projections allow for better predictability of future earnings and non-cash charges.
Detailed definition
This represents the projected amortization expense for finite-lived intangible assets for the year 2029. It is a forward...
Peer comparison
Standard disclosure for banks with significant historical acquisition activity.
Metric ID:
other_finite_lived_intangible_assets_amortization_expens_a9462eHistorical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.60B | $1.60B | $1.60B | $2.10B | $3.30B |
| QoQ Change | — | +0.0% | +0.0% | +31.3% | +57.1% |
| YoY Change | — | +0.0% | +0.0% | +31.3% | +57.1% |
Range$1.60B – $3.30B
CAGR+106.3%
Avg YoY Growth+22.1%
Median YoY Growth+15.6%
Current Streak4+ quarters growth
2029 at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s 2029?
- Merck & Co. (MRK) reported 2029 of $3.30B in Q4 2025.
- How has Merck & Co.'s 2029 changed year-over-year?
- Merck & Co.'s 2029 increased by 57.1% year-over-year, from $2.10B to $3.30B.
- What is the long-term trend for Merck & Co.'s 2029?
- Over 5 years (2020 to 2025), Merck & Co.'s 2029 has grown at a 18.7% compound annual growth rate (CAGR), from $1.40B to $3.30B.
- What does 2029 mean?
- The expected non-cash expense for acquired intangible assets in the year 2029.